

Meet Novartis Management 2025



Speaker biographies

Meet Novartis Management 2025

Corporate	Immunology	Cardiovascular, Renal & Metabolic	Oncology	Neuroscience
Vas Narasimhan	Victor Bulto	Patrick Horber	Shreeram Aradhye	Fiona Marshall
Harry Kirsch	Angelika Jahreis	Ruchira Glaser	Dushen Chetty	Norman Putzki
Mukul Mehta	Richard Siegel	Shaun Coughlin	Shiva Malek	Bob Baloh
Ronny Gal	Ingrid Zhang	Dianne Auclair Rocha	Reshema Kemps-Polanco	Tracy Dawson
Steffen Lang				



Vas Narasimhan

Chief Executive Officer

Since becoming CEO of Novartis in 2018, Vas has led a strategic and cultural transformation to build a fully focused medicines company—one that delivers high-value medicines that alleviate society's greatest disease burdens through technology leadership in R&D and novel access approaches. He leads a company of more than 78,000 associates that does business in approximately 130 countries and that reached nearly 300 million patients with innovative medicines in 2024.

Over the last five years, Vas has sharpened the company's focus on key therapeutic areas and technology platforms, including siRNA, radioligand, and gene and cell therapies, to deliver new medicines for patients with cardiovascular disease, cancer and rare but debilitating genetic disorders. In parallel, he has led a transformation to make culture a driver of innovation, reputation and performance at Novartis, while advancing a digital revolution to use data science and technology to find new ways to discover and develop medicines and increase efficiency.

Vas has focused his education and career on improving human health and on his personal purpose of inspiring a healthier world. During and after his medical studies, he worked on public health issues such as HIV/AIDS, malaria and tuberculosis in India, Africa and South America. He continues to champion access and global health priorities, including through a commitment by Novartis to expand access to innovative medicines in low- and middle-income countries by at least 200% by 2025.

Since joining Novartis in 2005, Vas has held a range of leadership roles, including Global Head of Development for Novartis Vaccines, and Global Head of Drug Development and Chief Medical Officer. In recognition of his sustained efforts to improve human health, he is an elected member of the National Academy of Medicine in the US, and a member of the board of fellows at Harvard Medical School. Vas previously served as chair of the Pharmaceutical Research and Manufacturers of America (PhRMA) and remains on its board of directors.



Harry Kirsch

Chief Financial Officer

As CFO of Novartis, Harry Kirsch is responsible for steering the company's strategy to maintain a strong financial position, support future innovation, and deliver long-term sustainable value to stakeholders. He has held this position since 2013.

Harry's role includes identifying and executing mergers, acquisitions, and other business development and licensing deals that help reinforce the company's pipeline and strengthen long-term value creation. Major milestones include the acquisition of GSK's oncology products in 2015, the divestiture of the Vaccines and Animal Health divisions, the creation of an OTC joint venture with GSK, and the divestiture of that stake in 2018. He also oversaw the spin-off of Alcon in 2019—the largest healthcare spin-off in Europe—and the acquisitions of AveXis and Advanced Accelerator Applications in 2018, and The Medicines Company in 2020.

Another area of focus is to support the integration of environmental, social and governance standards into core Novartis business operations. In 2020, Harry oversaw the issuance of a sustainability-linked bond, the first of its kind in the healthcare industry, which reinforces the company's commitment to its patient access targets.

Under Harry's leadership, Finance is helping to drive the digital transformation of Novartis, with artificial intelligence increasingly used for budgeting, forecasting and basic analytical tasks. He is a passionate supporter of inclusive communities, and of learning and talent development through coaching and mentoring programs, and established a Finance Academy to promote technical and leadership skills.

Harry joined Novartis in 2003. He became CFO of Pharma Europe in 2008, and CFO of the former Pharmaceuticals Division in 2010.



Mukul Mehta

Head BPA, Digital Finance & Tax (incoming CFO)

Mukul Mehta has served as Head of Business Planning and Analysis (BPA), Digital Finance and Tax since April 2025.

Since joining Novartis in March 2003, Mukul has built a diverse and global career in finance, holding finance roles of increasing responsibility across Commercial, Development, Financial Reporting & Accounting, Corporate Finance, and Business Services. His journey has taken him through Czech Republic, Norway, Poland, Switzerland, and France, culminating in leadership positions such as CFO International and CFO of Novartis Business Services. Prior to Novartis, Mukul worked in India's Heavy Engineering and Banking sectors. He holds an MBA from INSEAD, Fontainebleau, France.

Originally from India, Mukul holds dual nationality (French/Indian) and has been based in Basel for the past several years.



Ronny Gal

Chief Strategy & Growth Officer

In his role as Chief Strategy & Growth Officer, Ronny is responsible for the end-to-end portfolio strategy of Novartis to support the company's long-term growth, including oversight of corporate strategy, research and development portfolio strategy and business development.

Ronny joined Novartis in July 2022, bringing over 20 years of experience in the life-sciences industry spanning financial research and analytics, management consulting, and business development. As a thought leader in the healthcare sector, Ronny is recognized for his deep thematic research across therapeutic areas, technology platforms, and key industry topics such as US healthcare reform.

Prior to joining Novartis, Ronny was the senior analyst covering the US biopharmaceutical industry at Sanford Bernstein, a New York-based research and brokerage firm. Before joining Sanford Bernstein, Ronny started his career with the Boston Consulting Group, where he focused primarily on healthcare.

Ronny holds a doctorate in biochemistry from the Massachusetts Institute of Technology and a bachelor's degree in chemistry from Emory University, both in the US.



Steffen Lang

President, Operations

As President, Operations, Steffen Lang leads a team of 25,000 associates dedicated to manufacturing and supplying high-quality medicines to patients and providing operational support and high-quality services to the entire Novartis enterprise. Operations at Novartis incorporates the company's manufacturing, quality, and supply organization, as well as technology, data and digital, procurement, environmental sustainability, facility services, and global business services.

Prior to taking on this role, Steffen was Global Head of Novartis Technical Operations (NTO). Under his leadership, NTO underwent a transformation to become one of the leading manufacturing and supply organizations in the industry, providing agile, efficient support to the business, and reliably delivering life-changing medicines to patients around the world. During this time, the unit adapted its manufacturing capacity and capabilities to the changing needs of the Novartis strategy and product portfolio, maximizing the potential of its assets and expertise. As well as delivering technological innovation to enable the production of advanced therapeutic platforms, the unit collaborated with industry partners to support global demand for COVID-19 vaccines and therapies.

Steffen draws on a wealth of experience in the pharmaceutical industry, with a career that ranges from research through development to manufacturing and supply. He joined Novartis in 1994 as Head of Laboratory in Research and held positions of increasing responsibility before taking on his present role in 2022.



Victor Bulto

President, US

As President of the US unit for Novartis, Victor Bulto is pursuing a bold strategy to reimagine medicine and deliver on the company's responsibility to unlock the potential for helping patients in the world's largest healthcare market.

Victor is driven by the pressing need to translate medicines to outcomes for broad patient populations and transform the patient experience to help mitigate the challenges people living with disease face in getting diagnosed, obtaining medicine, and staying on treatment within the complex US healthcare system.

Prior to this role, Victor served as President, Novartis Pharmaceuticals Corporation, leading the US pharmaceuticals business. Victor has been with Novartis for 19 years and has broad, multinational experience in the healthcare industry. He has worked across every therapeutic area at Novartis Pharmaceuticals and played critical roles in launching numerous products.

He held various other positions at Novartis, including Head of the US Alcon Pharmaceuticals Franchise and Head of the Neuroscience Franchise for Region Europe, where he had responsibility for the overall strategy, growth and profitability of these businesses. Before joining Novartis, Victor was a medical device sales representative.

Victor has a strong track-record as a people-first leader with a focus on creating a culture where each individual can show up every day as their authentic self to best serve the interests of people living with disease.



Angelika Jahreis

Global Head, Immunology Development Unit

Angelika Jahreis is the Global Head of Immunology Development at Novartis, where she oversees the development portfolio and leads the development program teams across immunology. She is driving advancements in innovative medicine development for autoimmune and immune mediated diseases, including Cosentyx, Rhapsido, ianalumab, and rapidly manufactured CD19-CART therapy YTB323.

With over 20 years of experience in drug development, Angelika held positions of increasing responsibility at Gilead Sciences, Genentech and Amgen. Her work has been instrumental in the development of etanercept, rituximab and tocilizumab across multiple indications. A board-certified dermatologist and Leopoldina scholar, she conducted postdoctoral research at The Scripps Research Institute, deepening scientific understanding of autoimmune mechanisms.

Prior to joining Novartis in 2020, she served as Vice President of Rheumatology and Autoimmunity at Gilead. She has also collaborated closely with the FDA, contributing to the creation of the CARRA Consolidated Safety Registry (CoRe) for pediatric rheumatology and advancing regulatory discussions on long-term benefit assessment in osteoarthritis.



Richard Siegel

Global Head, Immunology, Biomedical Research

Richard Siegel is Global Head of Immunology at Novartis Biomedical Research in Basel, Switzerland. In this position, Richard oversees the discovery of new immune-modulating therapeutics for autoimmune and inflammatory diseases across the priority areas of Novartis.

Richard joined Novartis in 2018 after a long career in academic medicine and research. After training as a Rheumatologist and Immunologist at the University of Pennsylvania School of Medicine, Richard did his post-doctoral training and was on the faculty of the NIH intramural research program, in Bethesda, Maryland, where he was most recently Chief of the Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) conducting basic and translational research in cytokine biology. He was also Clinical Director of the NIAMS, overseeing the clinical research program encompassing interventional and natural history studies of genetic autoimmune and inflammatory syndromes and more common rheumatologic and dermatologic diseases, and contributed to the understanding of multiple genetic immune dysregulation syndromes. He has received numerous honors, including election to the American Society of Clinical Investigation and American Association of Physicians, and has authored more than 150 publications.

As the head of Translational Medicine for Immunology at Novartis from 2018 to 2023, Richard oversaw the transition of new molecular entities from the laboratory through early clinical trials to treat a broad spectrum of autoimmune conditions in Rheumatology, Dermatology and adjacent disease areas. Richard led a collaborative effort within Novartis to initiate clinical trials with the next-generation rapidly manufactured CD19-CART therapy YTB323 for autoimmune diseases. He also co-led the integrated Translational Research group in Immunology. He has worked with external translational research consortia, including IMI/IHI initiatives and the NIH-AMP-AIM program.

In 2023, Richard was appointed as the Immunology Research Disease Area Head, where he oversees a pre-clinical portfolio of immunomodulatory molecules being developed for immunology, as well as neuroscience, cardiovascular and renal indications. He also has had an active role in in-licensing or acquiring early-stage drug candidates from biotechnology companies, including STING inhibitors, VAV1 molecular glue degraders and anti-IL15 antibodies. As research head, Richard continues to follow his long-term passion to bridge the gap between laboratory and clinical research and discover new treatments to improve the lives of patients with autoimmune and inflammatory diseases.



Ingrid Zhang

Chief Commercial Officer, International

Ingrid Zhang is the Chief Commercial Officer, International, leading the Commercial Launch Strategy team since June 2024. The CLS team is responsible for developing and implementing strategies for new product launches. For established brands, the team focuses on expanding patient impact by optimizing commercial strategies and strengthening execution.

Previously, Ingrid was President & Managing Director of Novartis China from 2023 to 2024. In this role, Ingrid drove long-term strategic planning, accelerated growth across China, enhanced patient access to innovative medicines, and strengthened trust with society.

From 2017 to 2023, Ingrid served as President of Novartis Pharmaceuticals China, driving strong and consistent growth in the country. Before that, Ingrid was Country Pharma Organization Head and Country President in Poland from 2015 to 2017, leading commercial operations and strategic initiatives.

Prior to joining Novartis in 2011, Ingrid held management roles at AstraZeneca and Pfizer across multiple geographies and therapeutic areas. She began a career at McKinsey & Company, focusing on healthcare consulting.

In addition to these leadership roles, Ingrid is a member of the Board of Directors of Mettler-Toledo International Inc., a global leader in precision instruments and services.

Ingrid holds a master's degree in chemical engineering from Pennsylvania State University and an MBA from the Wharton School of the University of Pennsylvania.



Patrick Horber

President, International

As President of the International unit for Novartis, Patrick Horber focuses on strengthening and growing the company's business in Europe, Asia, Africa, Australasia, Canada and Latin America.

Patrick has more than 20 years of experience in the biopharma sector. A proven leader with a deep understanding of the global pharmaceutical market, Patrick has significant experience enabling commercial performance on a global scale.

Patrick joined Novartis from AbbVie, where he served as senior vice president AbbVie and president, Immunology. He was responsible for their Immunology Business Unit, leading the global strategy including global commercial development and the US execution. Prior to this role, as President, US Commercial Operations, Immunology, he successfully led the launch of two major immunology medicines in multiple indications in the US market and held a variety of leadership and general management positions in the US and in Europe.

Before joining AbbVie, Patrick held positions of increasing responsibility at Roche across diverse therapeutic areas including oncology, hematology, cardiometabolism, virology and anemia. He began his career in the healthcare practice of A.T. Kearney International.

Patrick holds a doctor of medicine from the University of Zurich in his native Switzerland. He speaks five languages.



Ruchira Glaser

Global Head, Cardiovascular, Renal & Metabolic Development Unit

Ruchira Glaser is the Global Head of Cardiovascular, Renal and Metabolic (CRM) Development at Novartis, where she oversees the development portfolio, driving therapeutic strategies and innovative medicines development across the cardiovascular, renal and metabolic portfolio.

With over 15 years of industry experience and 10 years of academic experience at the Hospital of the University of Pennsylvania, she has been instrumental in advancing clinical capabilities across global teams and driving internal and external innovation in the portfolio. Before this role, Ruchira was SVP, Global Head of Clinical Development at Novartis, where she led the clinical function, responsible for clinical development across all the core therapeutic areas of Novartis.

Before joining Novartis, Ruchira held senior roles in drug development at Moderna and GSK, including Therapeutic Area Head for Cardiovascular, Rare and Immunology at Moderna. She held positions of increasing breadth and responsibility at GSK, including Global Head of Clinical Sciences. Prior to joining industry life sciences, she began her career as an Interventional Cardiologist and full-time attending faculty as Assistant Professor of Medicine in the Cardiovascular Division at the University of Pennsylvania, where she focused on specialized cardiovascular clinical research and interventional cardiovascular care.

Ruchira holds a Doctor of Medicine and a Bachelor of Science from Cornell University, as well as a Master's degree in Clinical Epidemiology and Biostatistics from the University of Pennsylvania. A Fellow of the American College of Cardiology, she has dedicated her career to advancing both cardiovascular and broader disease care, driving innovative medicines development, and improving patient outcomes worldwide.



Shaun Coughlin

Global Head, Cardiovascular & Metabolic, Biomedical Research

Shaun Coughlin is the Global Head of Cardiovascular and Metabolism (CVM) at Novartis Institutes for BioMedical Research (NIBR). Since joining Novartis in 2017, he has led efforts in four critical areas of unmet medical need: atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, and obesity.

Shaun received his M.D. from Harvard Medical School and his Ph.D. from the Massachusetts Institute of Technology. He completed his residency in internal medicine at Massachusetts General Hospital and his cardiology and postdoctoral fellowships at the University of California, San Francisco (UCSF), where he served as Distinguished Professor in Cardiovascular Biology and Medicine and Director of UCSF's Cardiovascular Research Institute until joining Novartis in 2017.

His academic laboratory uncovered the molecular mechanism by which the coagulation protease thrombin activates platelets and other cells and the roles that this mechanism plays in vivo—a fundamental advance in our understanding of how normal and pathological blood clots form.

Beyond academia, Shaun has played influential roles in the biotech industry. Shaun was a co-founder and board member of COR Therapeutics, which produced eptifibatide, and served on the board of Millennium Pharmaceuticals. He has also held Scientific Advisory Board positions at several biotech and pharmaceutical companies.



Dianne Auclair Rocha

Therapeutic Area Head, Cardiovascular, Renal & Metabolic, US

Dianne Auclair Rocha is the Senior Vice President, Therapeutic Area Head for Cardiovascular, Renal & Metabolic (CRM) at Novartis. In this role, she is responsible for the cross-functional strategy and commercialization of the current and future (10+ year) CRM pipeline, balancing near-term performance and execution while shaping mid-to-long range strategy for the US business.

With nearly 30 years of experience, Dianne has held progressively senior leadership roles across US and global functions, with deep expertise in CRM, Neuroscience, and Respiratory.

Recognized for her inspirational leadership, Dianne empowers teams to reimagine possibilities for patients and cultivate belief-driven cultures. In 2024, she was honored as an HBA Luminary for her dedication to developing future leaders and her impactful leadership for patients.

As she continues her commitment to patients and the healthcare community, Dianne serves on the Global Board of Directors for the Healthcare Businesswomen's Association (HBA), and the HBA Foundation, and represents Novartis on the Healthcare Leadership Council.



Shreeram Aradhye

President, Development & Chief Medical Officer

As President, Development and Chief Medical Officer for Novartis, Shreeram Aradhye is responsible for advancing the Novartis pipeline of investigational medicines and overseeing medical activities across the company to bring meaningful new treatment options to patients.

Shreeram's organization leads the development of potential new medicines, running large clinical trials and steering the path to regulatory approval, while generating the evidence needed to ensure our medicines can reach all patients who can benefit. As part of the Novartis strategy, Shreeram and his team play a central role in driving the company's mid- to long-term growth and delivering on its purpose to improve and extend people's lives, with a strong pipeline that includes investigational high-value treatments for cardiovascular, renal and immunological conditions, neurological disorders and various forms of cancer.

Shreeram is passionate about partnering with patients and physicians to change medical practice, recognizing the hope and trust of clinical trial participants and those who treat and care for them. He has dedicated his professional career to improving patients' lives, first as an academic clinician and then as a drug developer and business leader.

Shreeram began his current role at Novartis in May 2022, rejoining the company after spending several years at US biotechnology companies, including leading the development of multiple clinical stage RNAi assets at Dicerna Pharmaceuticals. He first joined Novartis in 1999 and over the course of 20 years held a succession of leadership roles in the US, Switzerland, Germany and India, including Global Head of Medical Affairs for the Pharmaceuticals Business Unit and Development Head for the Neuroscience franchise.

Before joining the life sciences industry, Shreeram was an attending physician and assistant professor of medicine and a transplant nephrologist at the University of Pennsylvania. He completed his medical training at the All India Institute of Medical Sciences in 1989, after which he received additional specialty training in internal medicine and nephrology in the US.



Dushen Chetty

Global Head, Oncology & Hematology Development Unit (a.i.)

Dushen Chetty is the Global Head of Oncology Development (ad-interim) at Novartis, with end-to-end accountability for a portfolio spanning radioligand therapy (RLT), CAR-T and hematologic malignancies. He chairs the Oncology Development Leadership Team and serves on the Global Development Leadership Team, strengthening stage-gate governance and data-driven lifecycle innovation.

Under his leadership, Novartis has expanded the Pluvicto franchise, securing FDA approval for PSMAfore, advancing PSMAAddition to primary data, and initiating PSMA-DC, while pioneering Phase 0 imaging in RLT and shaping next-generation radioisotope and rational combination studies. He directs CAR-T strategy and has overseen regulatory interactions leading to approvals in Pediatric Glioma and tumor-agnostic BRAF indications. He also integrates external innovation through partnerships in AR degraders and DDR inhibitors and proposals for actinium-based studies.

Previously, Dushen was Senior Director at Janssen Oncology, advancing radioconjugates, immunotherapy, and BD&L initiatives, and at GlaxoSmithKline he led global licensing, late-stage programs, and established an R&D unit in Singapore. A Fulbright Scholar, he earned his PhD from Rutgers University and was a British Council Scholar at King's College London.



Shiva Malek

Global Head, Oncology, Biomedical Research

Shiva Malek is Global Disease Area Head of Oncology at BioMedical Research, the preclinical and early clinical innovation engine of Novartis.

Previously, Shiva was Vice President of Discovery Oncology at Genentech, accountable for oncology research and the company's targeted therapeutics oncology research portfolio. She joined Genentech in 2006 as one of the first scientists in its newly established small-molecule discovery team, and previously held positions of increasing responsibility at Vertex Pharmaceuticals and Exelixis.

Shiva is a world leader in RAS/RAF biology whose work has been critical to the discovery and validation of drug targets across multiple kinase signaling pathways in cancer. In 2021, she was selected by Endpoints as one of 20 top women leaders in biopharma R&D. In 2025, she was the winner of the AACR Award for Outstanding Achievement in Chemistry in Cancer Research.

Shiva earned her Ph.D. in biochemistry from the University of California San Diego.



Reshema Kemps-Polanco

Chief Commercial Officer, US

Reshema Kemps-Polanco is Executive Vice President and Chief Commercial Officer of Novartis US. In this role, she is responsible for the end-to-end commercialization across four therapeutic areas, including oncology, immunology, neurology, and cardiovascular/renal/metabolic conditions.

With 25 years of pharmaceutical industry experience, Reshema has extensive healthcare business leadership knowledge and sales and marketing expertise, and a demonstrated ability to oversee large commercial organizations across multiple therapeutic areas. Prior to rejoining Novartis in 2021, she held several leadership positions at Johnson & Johnson from 2014 until 2021, most recently serving as President, Janssen U.S. Cardiovascular & Metabolism and Janssen Pharmaceuticals Puerto Rico, where she was responsible for developing and delivering the business strategy and driving the growth initiatives for these businesses. Reshema began her career at Novartis in sales and held management positions of increasing responsibility, including leading the US commercial team's marketing strategy for its leukemia franchise and as US brand leader for its osteoporosis therapy.

Reshema serves on the Board of Directors for Charles Rivers Laboratories International and is a member of the CEO Roundtable on Cancer.



Fiona Marshall

President, Biomedical Research

Fiona Marshall is President of Biomedical Research, the company's innovation engine, where she leads approximately 5,500 scientists and other associates across nine research sites dedicated to the discovery of high-value medicines for patients.

Fiona collaborates with experts across the pipeline—from R&D to manufacturing and commercial development—to ensure Biomedical Research's technological and scientific breakthroughs translate into therapies that address the world's greatest disease burdens.

Prior to taking up her current role in November 2022, Fiona served as senior vice president and global head of discovery sciences, preclinical development and translational medicine at MSD (Merck & Co in the US). Prior to that, she was a founder and chief scientific officer of Heptares Therapeutics, a UK-based biotechnology company focused on structure-based drug design. Earlier in her career, Fiona was director of molecular pharmacology at Millennium Pharmaceuticals and spent 10 years at GSK, holding senior positions in molecular pharmacology and neuroscience.

Fiona holds a bachelor's degree in biochemistry from University of Bath and a doctorate in neuroscience from the University of Cambridge, both in the UK. She was the recipient of the 2012 WISE Women of Outstanding Achievement for Innovation and Entrepreneurship Award, the 2015 RSC Malcolm Campbell Award for Chemistry, and the Vane Medal from the British Pharmacological Society. She is also a fellow of the Royal Society and the Academy of Medical Sciences, and an honorary fellow of both the British Pharmacological Society and the Royal Society of Chemistry.



Norman Putzki

Global Head, Clinical Development

Norman Putzki is the Global Head of Drug Development, Neuroscience and Gene Therapy, and the US Development Site Head at Novartis. He joined the global development organization of Novartis in 2013 and has since taken various leadership roles in drug development, and he also previously led the Novartis US medical organization. During his tenure, he has been leading teams around the globe to develop new medicines in his field, leading to several new indications and approvals of new medicines.

Norman's background is in academic neurology/neuroscience. During his academic career in clinical neurology in various settings, his focus was on inflammatory disorders of the central nervous system such as Multiple Sclerosis (MS). Norman led clinical and research groups in two academic centers before joining pharma industry in 2010 (initially in Medical Research, Biogen Idec, Cambridge, MA, US).

Norman studied Human Medicine in Germany, the United Kingdom (University College London), and Switzerland (University of Berne) and graduated from Essen University (Essen, Germany) as M.D. While pursuing medical training with focus on Neurology, he earned his PhD in the Department of Neurology at Essen University by investigating the NDMA pathway in Parkinson's Disease. Norman performed residency training in Internal Medicine and Neurology at University of Essen, Germany, University College London (Institute of Neurology Queen's Square, UK) and University of Berne (Switzerland).

Norman is an author/co-author of >50 peer reviewed publications and he authored 4 books, mainly in the areas of clinical neurology, and translational work with regulatory T cell function, as well as epidemiologic aspects of MS. He is a fellow of the American Academy of Neurology.



Bob Baloh

Global Head, Neuroscience, Biomedical Research

Bob Baloh is the Global Head of Neuroscience at Biomedical Research, where he leads efforts to advance scientific discovery and therapeutic innovation in neurological diseases.

Dr. Baloh received his MD-PhD degree from Washington University and completed his neurology residency at Harvard's MGH/Brigham hospitals in Boston. He returned to Washington University for a fellowship in neuromuscular diseases and then joined as junior faculty to develop research programs focused on understanding the molecular mechanisms of neurologic diseases using insights from human genetics.

In 2011, Dr. Baloh moved to Cedars-Sinai Medical Center in Los Angeles where he headed the Division of Neuromuscular Medicine, the Center for Neural Science and Medicine, was Vice Chair of Neurology research, and a Professor in Neurology at UCLA and Cedars-Sinai. There he developed programs in neuromuscular diseases with emphasis on ALS/frontotemporal dementia, Charcot-Marie-Tooth disease, and muscular dystrophies with a focus on multidisciplinary patient care and clinical research. He continued to run a successful basic laboratory research program studying molecular and cellular mechanisms underlying neurodegenerative disease.

Before joining Novartis in 2021, Dr. Baloh was Vice President and Head of Research in Neuroscience and Rare Diseases at Roche Pharmaceuticals in Basel.



Tracy Dawson

Therapeutic Area Head, Neuroscience, US

Tracey Dawson is Senior Vice President and US Therapeutic Area Head for Neuroscience at Novartis. Her career spans over 25 years with roles in sales, marketing, product development, and leadership at companies including Novartis, Genentech, Shire, Biogen, and Eli Lilly, as well as venture funding in private biotech. She holds a PhD in Physical Organic Chemistry from the University of Hull, UK, and resides in the Boston area.

